港股异动 | 宜明昂科-B(01541)涨超7% IMC-002治疗中重度SLE Ib/II期初步数据以壁报形式于EULAR 2026公布

智通财经06-05

智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002(IMM0306)，在2026年欧洲抗风湿病联盟年会(EULAR 2026)上以壁报形式公布了其针对中重度活动性系统性红斑狼疮(SLE)患者的Ib/II期临床试验最新初步结果。数据显示...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2641712197?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-05 14:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641712197","market":"hk","top_or_hot":-1,"title":"港股异动 | 宜明昂科-B(01541)涨超7% IMC-002治疗中重度SLE Ib/II期初步数据以壁报形式于EULAR 2026公布","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002(IMM0306)，在2026年欧洲抗风湿病联盟年会(EULAR 2026)上以壁报形式公布了其针对中重度活动性系统性红斑狼疮(SLE)患者的Ib/II期临床试验最新初步结果。数据显示...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1450622.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B(01541)涨超7% IMC-002治疗中重度SLE Ib/II期初步数据以壁报形式于EULAR 2026公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B(01541)涨超7% IMC-002治疗中重度SLE Ib/II期初步数据以壁报形式于EULAR 2026公布\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 14:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1450622.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002(IMM0306)，在2026年欧洲抗风湿病联盟年会(EULAR 2026)上以壁报形式公布了其针对中重度活动性系统性红斑狼疮(SLE)患者的Ib/II期临床试验最新初步结果。数据显示...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1450622.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4077","symbol_name":"互动媒体与服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1450622.html","article_id":"2641712197","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641712197","pubTimestamp":1780640370,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，宜明昂科-B涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002，在2026年欧洲抗风湿病联盟年会上以壁报形式公布了其针对中重度活动性系统性红斑狼疮患者的Ib/II期临床试验最新初步结果。据介绍，IMC-002是一款靶向CD20和CD47的双特异性融合蛋白。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4077":"互动媒体与服务","SLE":"Super League Gaming Inc.","01541":"宜明昂科-B","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard"},"translate_title":"Hong Kong stock changes | Yiming Angke-B (01541) rose by more than 7% IMC-002 treatment of moderate to severe SLE Phase Ib/II preliminary data announced in the form of a wall poster in EULAR 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1.5,"SLE":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002(IMM0306)，在2026年欧洲抗风湿病联盟年会(EULAR 2026)上以壁报形式公布了其针对中重度活动性系统性红斑狼疮(SLE)患者的Ib/II期临床试验最新初步结果。数据显示，IMC-002在实现深度B细胞清除的同时，展现出优异的安全性与耐受性，且临床疗效强劲持久。据介绍，IMC-002是一款靶向CD20和CD47的双特异性融合蛋白。其独特的分子设计旨在通过双重机制发挥作用：一方面利用CD20靶点介导抗体依赖性细胞介导的细胞毒性(ADCC)，另一方面通过阻断CD47“别吃我”信号来增强抗体依赖性细胞吞噬作用(ADCP)，从而更高效地清除致病B细胞。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641712197","isCrawlerRequest":true}